L Sutherland
Overview
Explore the profile of L Sutherland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
1386
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sutherland L, McGarty A, Melville C, Hughes-McCormack L
J Intellect Disabil Res
. 2021 Feb;
65(5):405-436.
PMID: 33590605
Background: Children and adolescents with intellectual disabilities (ID) participate in low levels of physical activity. To inform the development of interventions, we need to better understand factors associated with physical...
2.
Campieri M, Gilat T, Hanauer S, Korelitz B, Lauritsen K, Malchow H, et al.
Inflamm Bowel Dis
. 2013 Jan;
2(4):265-7.
PMID: 23282593
No abstract available.
3.
Hanauer S, Sutherland L
Inflamm Bowel Dis
. 2013 Jan;
2(2):121.
PMID: 23282519
No abstract available.
4.
5.
Sutherland L, MacDonald J
Cochrane Database Syst Rev
. 2006 Apr;
(2):CD000544.
PMID: 16625537
Background: The newer 5-ASA preparations were intended to avoid the adverse effects of SASP while maintaining its therapeutic benefits. The efficacy and safety of 5-ASA preparations have been evaluated in...
6.
Sutherland L, MacDonald J
Cochrane Database Syst Rev
. 2006 Apr;
(2):CD000543.
PMID: 16625536
Background: The newer 5-ASA preparations were intended to avoid the adverse effects of SASP while maintaining its therapeutic benefits. The efficacy and safety of 5-ASA preparations have been evaluated in...
7.
Sutherland L, MacDonald J
Cochrane Database Syst Rev
. 2003 Aug;
(3):CD000543.
PMID: 12917894
Background: The newer 5-ASA preparations were intended to avoid the adverse effects of SASP while maintaining its therapeutic benefits. The efficacy and safety of 5-ASA preparations have been evaluated in...
8.
Sutherland L, Roth D, Beck P, May G, Makiyama K
Cochrane Database Syst Rev
. 2003 Jan;
(4):CD000544.
PMID: 12519547
Background: The newer 5-ASA preparations were intended to avoid the adverse effects of SASP while maintaining its therapeutic benefits. The efficacy and safety of 5-ASA preparations have been evaluated in...
9.
Schroy 3rd P, Geller A, Crosier Wood M, Page M, Sutherland L, Holm L, et al.
Prev Med
. 2001 Oct;
33(5):381-91.
PMID: 11676578
Background: Physician noncompliance with screening recommendations has been a major barrier to effective colorectal cancer control. The overall objectives of this study were to assess the current attitudes and screening...
10.
Wang D, Chang P, Wang Z, Sutherland L, Richardson J, Small E, et al.
Cell
. 2001 Jul;
105(7):851-62.
PMID: 11439182
Serum response factor (SRF) regulates transcription of numerous muscle and growth factor-inducible genes. Because SRF is not muscle specific, it has been postulated to activate muscle genes by recruiting myogenic...